Impact of Hospital-Administered Extended-Release Naltrexone on Readmission Rates in Patients With Alcohol Use Disorder: A Pilot Study

Jeremy Tigh, PharmD; Kristin Daniel, PharmD, BCPS, D-PLA; Alëna A. Balasanova, MD

Prim Care Companion CNS Disord 2022;24(6):22m03213

ABSTRACT

Objective: To evaluate the impact of extended-release (ER) intramuscular naltrexone on readmission rates for hospitalized patients with alcohol use disorder (AUD).

Methods: This was a single-center, retrospective before and after study. Adult patients with AUD who received ER naltrexone prior to discharge between June 29, 2020, and November 30, 2020, were included in the study. The primary outcome measure was alcohol-related readmission 90 days after ER naltrexone administration. Secondary outcomes were the number of emergency department visits, length of hospital stay, and time between hospital admissions. Patients served as their own controls before and after ER naltrexone administration, and data were collected from the electronic medical records. Comparative analysis was performed using descriptive statistics and paired Student t test.

Results: 58 patients received ER naltrexone during the study period, with a mean (SD) pre and post 90-day admission rate of 0.60 (1.14) and 0.71 (1.27), respectively, P = .56. Number of emergency department visits before and after the intervention were 0.5 (1.06) and 0.48 (1.40), respectively, P = .93. Length of hospital stay decreased after naltrexone administration (2.92 [1.95] vs 1.18 [1.78] days, P < .005).

Conclusion: There was no major difference in the number of hospitalizations or emergency department visits, but there was a decreased length of hospital stay in patients who received ER naltrexone prior to hospital discharge for the treatment of AUD.

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

References (20)

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association; 2013.
Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). SAMHSA website. Published online 2019. Accessed September 20, 2022. https://www.samhsa.gov/data/
Esser MB, Sherk A, Liu Y, et al. Morbidity and Mortality Weekly Report (MMWR). Deaths and Years of Potential Life Lost From Excessive Alcohol Use-United States, 2011–2015. 2020;69(39):1428–1433. CDC website. Accessed September 20, 2022. https://www.cdc.gov/mmwr/volumes/69/wr/mm6939a6.htm
Russo CA. Elixhauser A. Hospitalizations for Alcohol Abuse Disorders, 2003. HCUP Statistical Brief #4. AHRQ website. Published online 2006. Accessed September 20, 2022. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb4.pdf
Sacks JJ, Gonzales KR, Bouchery EE, et al. 2010 national and state costs of excessive alcohol consumption. Am J Prev Med. 2015;49(5):e73–e79. PubMed CrossRef
Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA. 2018;320(8):815–824. PubMed CrossRef
Reus VI, Fochtmann LJ, Bukstein O, et al. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018;175(1):86–90. PubMed CrossRef
Baser O, Chalk M, Rawson R, et al. Alcohol Dependence Treatments: Comprehensive Healthcare Costs, Utilization Outcomes, and Pharmacotherapy Persistence. 2011. Accessed September 20, 2022. AJMC website. www.ajmc.com
Kranzler HR, Wesson DR, Billot L; DrugAbuse Sciences Naltrexone Depot Study Group. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res. 2004;28(7):1051–1059. PubMed CrossRef
Garbutt JC, Kranzler HR, O’Malley SS, et al; Vivitrex Study Group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617–1625. PubMed CrossRef
Borg B, Douglas IS, Hull M, et al. Alcohol misuse and outpatient follow-up after hospital discharge: a retrospective cohort study. Addict Sci Clin Pract. 2018;13(1):24. PubMed CrossRef
Wei J, Defries T, Lozada M, et al. An inpatient treatment and discharge planning protocol for alcohol dependence: efficacy in reducing 30-day readmissions and emergency department visits. J Gen Intern Med. 2015;30(3):365–370. PubMed CrossRef
Stephens JR, Moore C, Stepanek KV, et al. Implementation of a process for initiating naltrexone in patients hospitalized for alcohol detoxification or withdrawal. J Hosp Med. 2018;13(4):221–228. PubMed CrossRef
Espiridion ED. A retrospective study of hospital recidivism among patients with alcohol use disorders treated with intramuscular naltrexone. Cureus. 2019;11(12):e6287. PubMed CrossRef
Beatty A, Stock C. Efficacy of long-acting, injectable versus oral naltrexone for preventing admissions for alcohol use disorder. Ment Health Clin. 2018;7(3):106–110. PubMed CrossRef
Busch AC, Denduluri M, Glass J, et al. Predischarge injectable versus oral naltrexone to improve postdischarge treatment engagement among hospitalized veterans with alcohol use disorder: a randomized pilot proof-of-concept study. Alcohol Clin Exp Res. 2017;41(7):1352–1360. PubMed CrossRef
Hartung DM, McCarty D, Fu R, et al. Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies. J Subst Abuse Treat. 2014;47(2):113–121. PubMed CrossRef
Mark TL, Montejano LB, Kranzler HR, et al. Comparison of healthcare utilization among patients treated with alcoholism medications. Am J Manag Care. 2010;16(12):879–888. PubMed CrossRef
Collins SE, Duncan MH, Saxon AJ, et al. Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomized clinical trial. Lancet Psychiatry. 2021;8(4):287–300. PubMed CrossRef
Malone M, McDonald R, Vittitow A, et al. Extended-release vs oral naltrexone for alcohol dependence treatment in primary care (XON). Contemp Clin Trials. 2019;81:102–109. PubMed CrossRef